M&A, Licensing, & IPO Report 1Q 2016

22 April 2016

Deal activity in the first quarter of 2016 started much in the same way as 2015 ended. A handful of high profile acquisitions and IPOs helped prop up the biotech and pharma sector, but ultimately political rhetoric and global events subdued the prior five year bull run seen in biotech and pharma. Read the report to get a snapshot of M&A, Licensing and IPO editorial coverage over 1Q16 combined with the top deal activity datasets from BioPharm Insight’s database.